CHENG CHENG1,2,3, CHAO SHI1,2, SHANG WU1,2, WEIXING WU3, JINGPING LI1,2, SINUO GAO1,2, MENG HAN3, YIMIN WANG3, XIANGMEI ZHANG2,4,*, YUNJIANG LIU1,2,*
Oncology Research, Vol.33, No.7, pp. 1633-1648, 2025, DOI:10.32604/or.2025.061637
- 26 June 2025
Abstract Objectives: While programmed cell death 1 (PD-1) inhibitors have improved cancer treatment, the function and mechanisms of programmed cell death ligand 1 (PD-L1), particularly when expressed by cancer cells, remain unclear. This study aims to explore the role of PD-L1 within breast cancer cells and identify key targets for future immunotherapy. Methods: RNA-seq was performed on breast cancer cells with silenced PD-L1 to screen for differentially expressed genes, followed by bioinformatics analysis. Clinical specimens from breast cancer patients undergoing primary surgery without preoperative treatment were collected, along with in vitro analysis to validate the potential mechanism. Results:… More >